 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
InMode Ltd. (INMD) designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies.
The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.
It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation.
InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries.
The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017.
InMode Ltd. reported 4th Quarter December 2020 earnings of $0.92 per share on revenue of $75.2 million. The consensus earnings estimate was $0.62 per share. Revenue grew 60.0% on a year-over-year basis.
The company said it expects 2021 non-GAAP earnings of $2.34 to $2.45 per share on revenue of $250.0 million to $260.0 million. The current consensus earnings estimate is $2.19 per share on revenue of $251.2 million for the year ending December 31, 2021.
Shares are forming a "bullish cup and handle" formation, which suggests that shares are ready to break higher.
Entry point: $71.00
52-week trade range: $13.14 - $73.00
Stop/Loss: $67.50
Target Price: $78.00
INMD closed at $79.00
